MedChemExpress

This installment of Supplier Spotlight® highlights MedChemExpress, a leading global supplier of high-quality life science reagents. Their services are available on Scientist.com.

1. What is your company’s mission?

MedChemExpress’s (MCE’s) mission is to deliver pharmaceutical, chemical and biological research products and services with rapid updates, efficient delivery and responsive support. Through our global warehouse network, fast shipping and continuously expanding compound portfolio, MCE empowers pharmaceutical and biotech researchers worldwide to accelerate their discovery and development programs — from early research to therapeutic advancement.

2. What products and services do you offer?

MCE is a global provider of high-quality life science reagents and drug discovery solutions, including:

• Over 150,000 bioactive small molecules targeting 30,000+ proteins across 20+ key signaling pathways, ideal for target validation, mechanism studies and early-stage drug discovery.
• High-quality antibodies and recombinant proteins supporting a broad range of biological research applications.
• More than 250 curated compound libraries and integrated discovery services, including DEL screening, high-throughput screening, kinase profiling, ion channel assays and custom synthesis.

3. What problems do you solve?

1. MCE Millions of Compounds that:

• Accelerate drug discovery by consolidating high-quality compound resources.
• Expand chemical space coverage to increase hit rates for novel targets and streamline lead optimization.
• Enable cost-effective R&D through diverse, small-scale, high-value compound libraries.
• Support more targeted development of new indications for existing drugs as well as innovative therapeutics.

2. MCE Isotope-Labeled Compounds that:

• Enable precise differentiation between endogenous substances and exogenously administered compounds.
• Overcome challenges related to low detection sensitivity and improve the accuracy of quantifying trace analytes in complex biological matrices.

4. What are the most innovative tools and technologies that you offer?

1. MCE Compound Libraries

• By continuously incorporating new molecules and leveraging an extensive data foundation, MCE enhances the diversity of biological activities and research stages represented in its compound libraries.
• Diversity Libraries are designed with a broad range of structural scaffolds and functional groups to maximize chemical space, enabling the discovery of novel biological effects. All compounds undergo rigorous pre-screening to ensure high drug-likeness and eliminate off-target motifs, making them well-suited for both high-throughput screening (HTS) and high-content screening (HCS).

Highlights include:

• Bioactive Compound Libraries: general bioactive screening libraries, drug repurposing collections, metabolism-focused libraries, compound characteristic – classified libraries, structure-classified libraries, signaling pathway – targeting libraries, disease-focused libraries and natural product series.
• Diversity Compound Libraries: distinctive diversity libraries, focused and target-specific libraries, lead-like structure – based libraries, DNA-encoded libraries and AI-enabled libraries.

2. MCE Isotope-Labeled Compounds

• MCE offers a comprehensive portfolio of stable isotope-labeled compounds to support applications such as deuterated drug development, pharmacokinetic and pharmacodynamic studies, metabolic pathway elucidation and disease mechanism research.
• To meet evolving research needs, MCE also provides customized synthesis services for isotope-labeled compounds, delivering tailored solutions for specialized scientific requirements.

5. What are your competitive advantages?

1. MCE Compound Libraries

• Bioactive Compound Libraries: Cover 1,000+ drug research targets with diverse subtype activities; include 200+ curated libraries built on literature and authoritative databases, with 30,000+ in-stock molecules.
• Diversity Libraries: Feature 80,000+ compounds with highly diverse chemical structures, including lead-like molecules with strong bioactivity and high target-binding potential — providing a reliable and rich resource for drug screening.
• Quality Assurance: ISO 9001 and CNAS certified facilities equipped with hundreds of advanced instruments, delivering rigorous quality reports, including HNMR, LC/MS, HPLC and SEC-HPLC.

2. MCE Isotope-Labeled Compounds

• Extensive In-Stock Availability: A broad product portfolio with above-average market availability.
• Efficient Supply Chain: A global warehouse network ensures fast delivery and reliable order fulfillment.
• Custom Isotope-Labeling Services: Tailored synthesis solutions to meet specific research needs — capabilities not widely available in the market.
• Stringent Quality Control: Comprehensive quality testing, including NMR, HPLC, LC-MS and isotopic enrichment analysis, ensuring high product quality and consistency.

6. Who are your clients?

1. MCE Compound Libraries:

• Academic and research institutions, including universities, institutes and hospitals
• Biotechnology companies and innovative drug developers
• Pharmaceutical companies
• Contract research organizations (CROs)
• Industrial sectors, including food, nutraceuticals, cosmetics and agriculture

2. MCE Isotope-Labeled Compounds:
MCE serves tens of thousands of clients worldwide, including universities, life science laboratories, pharmaceutical companies and CROs. By consistently delivering high-quality stable isotope-labeled products and customized synthesis services, MCE has earned the trust of prestigious academic institutions and leading pharmaceutical organizations.

7. What new products and services are you developing in 2026?

1. MCE Compound Libraries:

• Mini Bioactive Compound Library Series: Designed for higher efficiency and broad target coverage, these libraries feature optimized potency, diverse target profiles and a smaller, more cost-effective compound selection, including areas such as kinase, epigenetics, cell death and anti-aging.
• Potential-focused and target-specific libraries: Developed using AI-driven representations of known small-molecule data, combined with similarity screening against drug-like compound datasets to enhance target relevance and discovery efficiency.

2. MCE Isotope-Labeled Compounds:
In 2026, MCE will continue to advance innovation in isotope-labeled compounds, addressing cutting-edge research needs while expanding its portfolio of isotope-labeled internal standards for novel inhibitors. By developing internal standard solutions not currently available on the market, MCE aims to help researchers overcome experimental challenges and improve data accuracy and reliability.

8. Where are your laboratories and offices located?

MCE is headquartered in New Jersey, USA, at 1 Deerpark Drive, Suite F, Monmouth Junction, NJ 08852. The company has established warehouses and business centers across key global regions, including the United States, Europe, China, Japan and India.
MCE’s R&D and quality control network spans multiple cities in China, including Hefei, Yantai, and Nanjing, and is supported by GMP manufacturing facilities in Ma’anshan and Shanghai. In 2025, MCE further expanded its capabilities with the launch of the Chongqing Antibody & ADC Integrated GMP manufacturing site, strengthening its CDMO services.

Connect with MedChemExpress on Scientist.com